Statins: Within-group comparisons, statin escape and combination therapy

Current Opinion in Lipidology

Volumn 7, Issue 6, 1996, Pages 385-388

  Tikkanen, Matti J ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN;

CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS; MYOPATHY; PRIORITY JOURNAL; SHORT SURVEY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0030504865     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199612000-00008     Document Type: Short Survey

References (28)

1. Brown MS, Goldstein JL: Heart attacks: gone with the century? Science 1996, 272:629. A view from the vantage point.
2. Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ: Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994, 343:1554-1555.
3. ••].
4. Ose L, Scott R, the Simvastatin-Fluvastatin Study Group: Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995, 10:127-138. Two studies indicating that simvastatin is approximately seven times as effective as fluvastatin in lowering LDL-cholesterol.
5. Deslypere JP: Simvastatin-fluvastatin comparative study. Clin Drug Invest 1996, 11:362-363.
6. Jacotot B, Benghozi R, Pfister P, Holmes D: Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolemia. Am J Cardiol 1995, 76:54A-56A.
7. Nawrocki JW, Weiss SR, Davidson MH, Sprecher DL, Schwartz SL, Lupien P-J, Jones PH, Haber HE, Black DM: Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor Arterioscler Thromb Vasc Biol 1995, 15:678-682.
8. Illingworth DR: Long term administration of lovastatin in the treatment of hypercholesterolaemia. Eur Heart J 1987, 8E: 103-111.
9. Rubinstein A, Weintraub M: Escape phenomenon of low-density lipoprotein cholesterol during lovastatin treatment. Am J Cardiol 1995, 76:184-186. A study focusing on a subgroup (n = 26) of 233 patients receiving lovastatin 20 mg per day whose LDL-cholesterol levels increased by more than 10% during ongoing treatment. The authors considered impaired patient compliance, compensatory induction of HMG CoA reductase activity and induction of the statin-metabolizing cytochrome P-450 3A enzymes as possible explanations of this 'statin escape' phenomenon.
10. Brown MS, Faust JR, Goldstein JL, Kaneko I, Endo A: Induction of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity in human fibroblasts incubated with compactin (ML-236B), a competitive inhibitor of the reductase. J Biol Chem 1978, 253:1121-1128.
11. Sviridov DD, Endo A, Pavlov MY, Repin VS: Time response of cholesterol synthesis inhibition by compactin-related compounds. In vitro quantitation of the 'escape phenomenon'. Lipids 1993, 28:569-571.
12. Wang RW, Kami PH, Lu AY, Thomas PE, Guengerich FP, Vyas MP. Biotransformation of lovastatin. Identification of cytochrome P-450-3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes Arch Biochem Biophys 1991, 290:355-361.
13. Ojala J-P, Helve E, Karjalainen K, Tarkkanen A, Tikkanen MJ: Long-term maintenance of therapeutic response to lovastatin in patients with familial and non-familial hypercholesterolemia: a 3-year follow-up. Atherosclerosis 1990; 82:85-95.
14. Mabuchi H, Sakai T, Sakai Y, Yoshimura A, Watanabe A, Wakasugi T, Koizumi J, Takeda R: Reduction of serum cholesterol in heterozygous patients with familial hypercholesterolemia N Engl J Med 1983, 308:609-613.
15. Hagen E, Istad H, Bodd E, Eriksen H-M, Selvig V, Bard JM, Fruchart JC, Borge M, Wolf M-C, Pfister P: Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine. Eur J Clin Pharmacol 1994, 46:445-449.
16. Jacotot B, Banga JD, Waite R, Peters TK: Long-term efficacy with fluvastatin as monotherapy and combined with cholestyramine (A 156-Week Multicenter Study) Am J Cardiol 1995, 76:41A-46A.
17. Schrott HG, Stein EA, Dujovne CA, Davidson MH, Goris GB, Oliphant TH, Philips JC, Shawaryn GG: Enhanced low-density lipoprotein cholesterol reduction and cost-effectiveness by low-dose colestipol plus lovastatin combination therapy. Am J Cardiol 1995, 75:34-39.
18. Pierce LR, Wysowski DK, Gross TP: Myopathy and rhabdomyosis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990, 264:71-75.
19. Tikkanen MJ: Fibric acid derivatives. Curr Opin Lipidol 1992, 3:29-33.
20. Feher MD, Foxton J, Banks D, Lant AF, Wray R: Long-term safety of statin-fibrate combination treatment in the management of hypercholesterolemia in patients with coronary artery disease. Br Heart J 1995, 74:14-17. A long-term study of 102 patients, most of whom received bezafibrate 400 mg per day plus simvastatin 10-20 mg per day, did not reveal any occurrence of myalgia or marked elevations of creatine phosphokinase activity. The 'myopathy syndrome' has reportedly been associated with the combined use of statins and fibrates.
21. Smit JWA, Jansen GH, de Bruin TWA, Erkelens DW: Treatment of combined hyperlipidemia with fluvastatin and gemfibrozil, alone or in combination, does not induce muscle damage. J Cardiol 1995, 76:126A-128A.
22. Tikkanen MJ: Selection of appropriate type and intensity of lipid lowering therapy. Curr Opin Lipidol 1995, 6:360-364.
23. Laaksonen R, Jokelainen K, Laakso J, Sahi T, Härkönen M, Tikkanen MJ, Himberg J-J: The effect of simvastatin treatment on the concentrations of antioxidant vitamins in low density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 1996, 77:851-854.
24. Hutchesson ACJ, Moran A, Jones AF: Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. J Clin Pharmacy 1994, 19:387-389.
25. Eliav O, Schurr D, Pfister R Friedlander Y, Leitersdorf E: High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995, 76:76A-79A.
26. Leitersdorf E, Muratti EN, Eliav O, Peters TK: Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995, 76:84A-88A.
27. Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn J, Weiss SR, Keilson LM, Brown WV, Miller VT, Shurzinske LJ, Black DM: Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia JAMA 1996, 275:128-133. Atorvastatin, a novel member of the statin family, was shown to reduce not only LDL-cholesterol but also plasma triglyceride levels in a dose-dependent manner in hypertriglyceridemic patients.
28. Ericsson C-G, Hamster A, Nilsson J, Grip L, Svane B, de Faire U: Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996, 347:849-853. This angiographic study was the first designed to assess the effects of a fibrate on progression of coronary atherosclerosis in men who had suffered a myocardial infarction. Eighty-one patients completed the 5 year study receiving either placebo or bezafibrate 200 mg three times daily. Bezafibrate was shown to slow the progression of atherosclerosis and to reduce clinical events despite the fact that LDL-cholesterol levels remained stable.